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Abstract
Background: The Na+, K+, 2Cl- type I cotransporter (NKCC1) and TRPV1 receptors, at the level
of the dorsal horn, have been implicated in mediating allodynia in response to an inflammatory
insult. The NKCC1 cotransporter regulates intracellular [Cl-] and thus the magnitude and polarity
of GABAA receptor responses in neurons. TRPV1 receptors transduce diverse chemical and
natural stimuli in nociceptors and are critical for inflammatory hyperalgesia.
Results: Here we have tested the role of spinal NKCC1 cotransporters and TRPV1 receptors in
referred allodynia in a model of visceral hyperalgesia in mice. Intrathecal (IT) injection of the
NKCC1 inhibitor bumetanide (BUM, 1 nmol) inhibited referred, abdominal allodynia evoked by an
intracolonic capsaicin injection. BUM was effective when injected IT either before or up to 4 hrs
after the establishment of referred allodynia. The TRPV1 antagonist AMG 9810 (1 nmol) also
inhibited referred allodynia in this model suggesting the involvement of an endogenous TRPV1
agonist in the dorsal horn in referred allodynia. In support of this suggestion, the endovanilloid
TRPV1 agonist, narachidonoyl- dopamine (NADA, 1 or 10 nmol, IT) evoked stroking allodynia in
the hindpaw that was blocked by co-treatment with AMG 9810 (1 nmol). The TRPV1-dependent
stroking allodynia caused by NADA appeared to be functionally linked to NKCC1 because BUM (1
nmol) also inhibited NADA-evoked stroking allodynia.
Conclusion: Our findings indicate that spinal NKCC1 and TRPV1 are critical for referred allodynia
mediated by a painful visceral stimulus. Moreover, they suggest that endogenous TRPV1 agonists,
released in the CNS in painful conditions, might stimulate TRPV1 receptors on primary afferents
that, in turn, play a role in increasing NKCC1 activity leading to allodynia.
Background
Intracellular chloride concentration in neurons is main-
tained by members of the Na+, K+, 2Cl- (NKCC) and K+,
Cl- (KCC) families of cation-chloride cotransporters [1].
The NKCC proteins accumulate chloride intracellularly
and, in dorsal root ganglion (DRG) neurons, it is the pri-
mary mechanism that sets the reversal potential for chlo-
ride conductance through GABAA-receptors (GABAAR)
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[2,3]. Unlike most CNS neurons, DRG neurons maintain
depolarizing responses to GABAAR agonists throughout
postnatal development [2,3]. These depolarizing GABAAR
responses are dependent on NKCC1 expression because
depolarizing GABAAR responses in DRG neurons are
reduced in NKCC1-/- mice [3]. It has been suggested that
some pain states might involve enhancements of primary
afferent GABAAR responses such that the normal small
GABAergic epolarization of these fibers is augmented to
the point that it induces a direct activation of spinal noci-
ceptors [4-7]. This has led to the proposal that NKCC1 is
responsible for the increase in intracellular chloride that
could mediate GABAAR-dependent depolarization above
threshold for spike generation in nociceptors [5-7]. In
support of this hypothesis, it has been shown that
NKCC1-/- mice display reduced responses to noxious heat
as well as reduced touch-evoked pain [3,8]. Furthermore,
intrathecal delivery of the NKCC1 blocker bumetanide
(BUM) inhibits nocifensive behavior in phase II of the for-
malin test [9] and mechanical allodynia induced by cap-
saicin injection into the hindpaw [10] in rats. Finally,
intracolonic capsaicin injection stimulates a rapid and
transient increase in spinal phosphorylated NKCC1 and a
long lasting increase in trafficking of NKCC1 protein to
the plasma membrane [11]. Taken together these findings
indicate that NKCC1 might play an important role in
inflammatory and tissue damage pain.
In naive animals, Aα-fiber stimulation causes a GABAAR-
dependent primary afferent depolarization (PAD) of noci-
ceptors leading to a decrease in pain transmission in the
spinal dorsal horn [7,12]. In inflammatory conditions Aβ-
fibers are capable of directly exciting nociceptors via a
GABAergic mechanism causing antidromic (termed dor-
sal root reflexes, DRRs) and orthodromic firing of nocice-
ptors [13-16]. This process has been proposed as a
mechanism of inflammation- or injury-evoked allodynia.
Because it is dependent on depolarizing GABAAR
responses, NKCC1 is a logical molecular candidate for
mediating this effect [5-7]. Here we have tested the
hypothesis that spinal NKCC1 mediates referred allody-
nia in response to a visceral inflammatory stimulus.
TRPV1 receptors in the CNS, likely localized on primary
afferent terminals in the dorsal horn, have recently been
identified as an important target for inflammatory allody-
nia [17]. Hence, we have also tested the hypothesis that
spinal TRPV1 receptors are involved in referred allodynia
and we have investigated a possible link between spinal
TRPV1-dependent allodynia and NKCC1. Our findings
demonstrate that spinally applied inhibitors of NKCC1
and TRPV1 attenuate referred allodynia evoked by a pain-
ful visceral stimulus and show that spinally applied
TRPV1 agonists cause allodynia that is likewise inhibited
by NKCC1 blockade.
Results
Spinal NKCC1 blockade inhibits intracolonic capsaicin-
evoked referred, abdominal allodynia and hyperalgesia
Work from this laboratory has shown previously that an
intracolonic capsaicin injection causes a transient increase
in NKCC1 phosphorylation and a sustained increase in
plasma membrane localization of NKCC1 in the spinal
dorsal horn [11]. Here we have tested the hypothesis that
NKCC1 is functionally linked to referred allodynia and
hyperalgesia in this model using spinal application of the
NKCC1 inhibitor bumetanide (BUM). We first sought to
determine the effects of increasing doses of intrathecal
(IT) BUM by itself and the effects of IT BUM on referred
(abdominal) allodynia and hyperalgesia 0.5 hrs following
an intracolonic capsaicin (0.1%) injection. In this model
referred allodynia peaks at 20 min post capsaicin injec-
tion, is sustained at this peak level for 6 hrs, and referred
allodynia is evident for at least 24 hrs [18,19]. BUM at 0.1,
1 and 10 nmol had no effect on response frequencies to 1
(Fig 1A) or 32 mN (Fig 1B) stimulation of the abdomen.
When BUM, at the same doses, was injected IT 5 min prior
to intracolonic capsaicin it dose-dependently inhibited
referred allodynia (1 mN stimulation of the abdomen, Fig
1C) and 1 nmol BUM inhibited referred hyperalgesia (32
mN stimulation of the abdomen, Fig 1D). BUM (1 nmol)
had no effect on nocifensive responses evoked by intraco-
lonic capsaicin (VEH = 88.0 ± 10.7 s, BUM = 78.5 ± 13.6
s) nor did it influence the latency to first nocifensive
behavior (VEH = 77.7 ± 17.4 s, BUM = 57.8 ± 12.9 s).
Next we addressed the time course of IT BUM effects on
the inhibition of intracolonic capsaicin-evoked referred
allodynia. BUM (1 nmol) was injected IT 5 min prior to
intracolonic capsaicin application and significantly inhib-
ited responses to 1 mN abdominal stimulation at 0.5 hrs
(Fig 2A). However, BUM injected mice developed referred
allodynia by 1 hr and this was maintained at 3 hrs illus-
trating that, while spinal NKCC1 blockade inhibits
referred allodynia, it does not prevent its subsequent
development (Fig 2A). If spinal NKCC1 activity contrib-
utes to the maintenance of referred allodynia we would
predict that IT BUM injection following intracolonic cap-
saicin would inhibit abdominal allodynia. When BUM (1
nmol) was injected IT 20 min following intracolonic cap-
saicin it inhibited referred allodynia 0.5 and 1 hr post cap-
saicin (Fig 2B). Three hrs following intracolonic capsaicin
the BUM group was not different from baseline (did not
display referred allodynia) but was also not different from
mice that received IT VEH. When BUM (1 nmol) was
injected IT 4 hrs post capsaicin it inhibited referred allody-
nia 0.5 and 1 hr post BUM injection (Fig 2C). At the 7 hr
time point the BUM group was not statistically different
from baseline (did not display referred allodynia) but was
also not different from the IT VEH group. These findings
indicate that spinal NKCC1 blockade either before or afterMolecular Pain 2007, 3:17 http://www.molecularpain.com/content/3/1/17
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intracolonic capsaicin is capable of inhibiting referred
allodynia.
Spinal TRPV1 receptors regulate referred allodynia: role of 
NKCC1
The role of TRPV1 in inflammatory hyperalgesia is well
established and appears to involve a peripheral mecha-
nism in which TRPV1 receptors are sensitized and
respond to lower temperature stimulation than their basal
thresholds [20,21]. It is also known that TRPV1 is
involved in inflammatory mechanical hyperalgesia and,
interestingly, recent studies have suggested that this effect
is due to TRPV1 receptors in the CNS, likely on primary
afferents in the dorsal horn [17]. Hence, we hypothesized
that spinal TRPV1 receptors might be involved in referred
allodynia in response to intracolonic capsaicin. The
TRPV1 antagonist AMG 9810 (1 nmol) [22] was injected
IT 5 min prior to intracolonic capsaicin and referred allo-
dynia (1 mN stimulation of the abdomen) was measured
at 0.5, 1.0 and 2.0 hrs. Mice that received an IT AMG 9810
injection did not differ from baseline at 0.5, 1.0 or 2.0 hrs
post intracolonic capsaicin injection while mice that
received an IT VEH injection displayed referred allodynia
at all time points (Fig 3). The AMG 9810 group was signif-
icantly decreased vs. VEH injected animals at the 0.5 hr
time point but not at 1.0 and 2.0 hrs (Fig 3). This obser-
vation illustrates that spinal TRPV1 receptors are involved
in referred allodynia evoked by an intracolonic capsaicin
injection.
The previous findings cited above and our present obser-
vation with AMG 9810 suggests that an endogenous
TRPV1 agonist is active in the spinal dorsal horn and is
involved in regulating mechanical nociceptive thresholds.
One such candidate endogenous TRPV1 agonist is n-ara-
chidonoyl-dopamine (NADA) [23]. NADA is a potent
TRPV1 agonist, causes hyperalgesia in vivo [23,24] and
exists in pharmacologically relevant concentrations in the
CNS [23,25]. We hypothesized that IT NADA would stim-
ulate allodynia and/or hyperalgesia in the hindpaw. 1 or
10 nmol NADA or VEH was injected IT and the hindpaw
was stimulated with 1 – 16 mN von Frey hairs 15 and 60
min following the IT injection. 1 nmol NADA had no
effect on von Frey response frequency at any time point
and 10 nmol NADA evoked hyperalgesia to an 8 mN stim-
ulus only at the 60 min time point (Fig 4A and 4B). We
also measured stroking allodynia as measured by stroking
the hindpaw with a cotton bud. Mice injected with 10
nmol NADA displayed stroking allodynia at both 15 and
60 min following IT NADA (Fig 4C and 4D). Mice injected
with 1 nmol NADA had stroking allodynia only at the 60
min time point (Fig 4D). We did not observe nocifensive
behaviors in response to NADA at either dose (data not
shown). This finding establishes that the TRPV1 agonist
NADA evokes stroking allodynia in the hindpaw follow-
ing spinal application. We next tested the ability of the
TRPV1 antagonist AMG 9810 (1 nmol) to block the effect
of NADA (10 nmol). AMG 9810 completely blocked
NADA-evoked stroking allodynia at 15 and 60 min post IT
injection (Fig 5A and 5B) indicating that the effects of
NADA are TRPV1-mediated.
Finally, we hypothesized that NADA-evoked stroking allo-
dynia would be attenuated by the NKCC1 blocker BUM.
When BUM (1 nmol) was co-injected with NADA stroking
allodynia was completely blocked 15 min following IT
injection (Fig 5C). Sixty min post injection BUM injected
mice did not differ from VEH but response frequency to a
stroking stimulus also did not differ from NADA injected
animals (Fig 5D). Hence, the NKCC1 inhibitor BUM
reduces spinally mediated TRPV1-dependent stroking
allodynia.
Discussion
In naive animals Aβ-fiber stimulation inhibits C-fiber
activity via a mechanism called primary afferent depolari-
NKCC1 inhibitor bumetanide blocks intracolonic capsaicin- evoked referred allodynia and hyperalgesia Figure 1
NKCC1 inhibitor bumetanide blocks intracolonic 
capsaicin-evoked referred allodynia and hyperalgesia. 
Three doses of bumetanide or vehicle (VEH) were injected 
intrathecally (IT) and saline or capsaicin was injected into the 
colon 5 min later. A and B) Baseline response frequencies to 
abdominal 1 mN and 32 mN von Frey hair application are 
shown as well as 30 min after the intracolonic (IC) saline 
injection. C and D) Response frequencies to abdominal 1 mN 
(C) and 32 mN (D) von Frey hair application 30 min after the 
IC capsaicin injection are shown in comparison to baseline 
von Frey response frequencies. Stars (*) indicate significant 
effects vs. baseline (two-way anova); number signs (#) indi-
cate significant effects of IT bumetanide injections (one-way 
anova, # or * p < 0.05, ** p < 0.01, *** p < 0.001; n = 6 per 
group).Molecular Pain 2007, 3:17 http://www.molecularpain.com/content/3/1/17
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zation (PAD) [7,12]. PAD is mediated by GABAARs on pri-
mary afferents where GABA has a depolarizing action. The
molecular mechanism for depolarizing GABAAR currents
appears to be expression of NKCC1 in DRG neurons lead-
ing to a high intracellular Cl- concentration and Cl- efflux
through the GABAAR channel upon pharmacological
stimulation [2,3]. We and others have proposed that
GABAergic mechanisms may explain allodynia in
inflamed conditions such that NKCC1 activity increases
leading to a large depolarization in C-fibers, causing spik-
ing, in response to Aβ-fiber stimulation [5-7]. Several lines
of evidence support this claim: 1) following an inflamma-
tory stimulus, lamina I neurons acquire a novel Aβ-fiber
input that is GABAergic in nature [13], 2) stroking allody-
nia following capsaicin injection into the hindpaw is
absent in NKCC1 knockout mice [8], 3) spinal applica-
tion of the NKCC1 blocker BUM inhibits intraplantar cap-
saicin-evoked, secondary mechanical allodynia in rats
[10] and 4) a painful visceral stimulus increases dorsal
horn NKCC1 phosphorylation and membrane trafficking
[11], both of which are mechanisms known to increase
NKCC1 activity and intracellular Cl-  concentrations
[1,26]. BUM also inhibits formalin  induced nocifensive
behaviors in the second phase of this model through both
a spinal and peripheral mechanism [9] although the rele-
vance of these findings to allodynia are not clear. Here we
have added to this line of evidence by demonstrating that
spinal application of BUM inhibits referred allodynia
evoked by capsaicin injection into the colon. Taken
together, these observations indicate that NKCC1 is an
important regulator of touch-evoked pain in inflamma-
tory conditions and that small molecules that inhibit this
Time course of NKCC1 inhibitor bumetanide blockade of  intracolonic capsaicin-evoked referred allodynia Figure 2
Time course of NKCC1 inhibitor bumetanide block-
ade of intracolonic capsaicin-evoked referred allody-
nia. Bumetanide (BUM) or vehicle (VEH) was injected 
intrathecally (IT) 5 min prior to intracolonic (IC) capsaicin 
(A) or 20 min (B) or 4 hrs (C) after IC capsaicin. Response 
frequencies to 1 mN von Frey hair application to the abdo-
men are shown at the indicated time points post IC capsaicin. 
Stars (*) indicate significant effects of BUM vs. VEH (two-way 
anova) while number signs (#) indicate significant effects vs. 
baseline (BL) at a given time point (one-way anova, # or * p < 
0.05, ## or ** p < 0.01, ### or *** p < 0.001; n = 6 per 
group).
Spinal TRPV1 antagonism inhibits intracolonic capsaicin- evoked referred allodynia Figure 3
Spinal TRPV1 antagonism inhibits intracolonic capsa-
icin-evoked referred allodynia. The TRPV1 antagonist 
AMG 9810 (AMG, 1nmol) was injected intrathecally (IT) 5 
min prior to intracolonic (IC) capsaicin. Response frequen-
cies to abdominal von Frey hair (1 mN) stimulation at the 
indicated time points post intracolonic capsaicin are shown. 
Stars (*) indicate significant effects of AMG vs. VEH (two-way 
anova) while number signs (#) indicate significant effects vs. 
baseline (BL, one-way anova) at a given time point (## p < 
0.01, ### or *** p < 0.001; n = 6 per group).Molecular Pain 2007, 3:17 http://www.molecularpain.com/content/3/1/17
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cotransporter might have clinical utility for allodynia in
humans.
Some pharmacological considerations deserve attention
with respect to IT BUM. The anti-hyperalgesic (32 mN
abdominal stimulation) effect of BUM was limited to a
narrow dose range (1 nmol). This is expected because
BUM possesses only roughly a 10–100 fold selectivity for
NKCC1 vs. KCC2 [27]. Inhibition of KCC2 by BUM
would be expected to have the opposite effect on touch-
evoked responses because decreased KCC2 expression
(analogous to pharmacological inhibition) or KCC2
blockade with DIOA reverses the polarity of GABAAR
responses in a subset of lamina I and II neurons, leading
to allodynia which has been proposed as a mechanism of
neuropathic pain [28]. KCC2 is not expressed by DRG
neurons [29] so this consideration applies only to intrin-
sic dorsal horn neurons. We focused on the 1 nmol dose
in the rest of the experiments because of the KCC2 consid-
eration stated above. While pretreatment with BUM
inhibited referred allodynia it did not block its develop-
ment. This finding likely reflects the long-lasting nocicep-
tive stimulus evoked by intracolonic capsaicin [19] and
illustrates that inhibition of NKCC1 is not sufficient to
block the development of referred allodynia. On the other
hand, BUM did effectively inhibit referred allodynia after
its establishment both at 20 min and 4 hrs post intraco-
lonic capsaicin injection suggesting that NKCC1 inhibi-
tors might be clinically useful in cases of established
inflammatory allodynia.
The TRPV1 receptor is expressed by a subset of DRG neu-
rons that project to lamina I and II of the dorsal horn [30].
The majority of these neurons also express NKCC1 [29],
hence, we reasoned that spinal TRPV1 receptors might be
involved in regulating NKCC1 activity. The role of TRPV1
receptors in thermal hyperalgesia is well established
[20,21] and, recently, it has become clear that spinal
TRPV1 receptors play a role in allodynia [17]. Our find-
ings show that spinal application of AMG 9810, a potent
and highly selective TRPV1 antagonist, inhibits referred
allodynia in response to intracolonic capsaicin. This sug-
gests that an endogenous TRPV1 agonist is active in this
model to evoke or maintain allodynia. One such potential
agonist is the endogenous vanilloid/cannabinoid NADA.
NADA is found in pharmacologically relevant concentra-
tions throughout the CNS [23] and its synthesis is regu-
Spinal TRPV1 agonist causes stroking allodynia in the hind- paw Figure 4
Spinal TRPV1 agonist causes stroking allodynia in the 
hindpaw. The endogenous TRPV1 agonist NADA (1 or 10 
nmol) or vehicle (VEH) was injected intrathecally (IT) and the 
hindpaws were stimulated with von Frey hairs of the indi-
cated calibers 15 (A) and 60 min (B) or a cotton bud 15 (C) 
and 60 min (D) after the IT injection. Stars (*) above columns 
indicate significant effects of NADA vs. VEH while number 
signs (#) above horizontal bars indicate significant effects of 
NADA 1 nmol vs. NADA 10 nmol (# or * p < 0.05; n = 10 
per group). Panels A and B, two-way anova; panels C and D 
one-way anova.
NADA-evoked stroking allodynia is TRPV1-dependent and  inhibited by bumetanide Figure 5
NADA-evoked stroking allodynia is TRPV1-depend-
ent and inhibited by bumetanide. The endogenous 
TRPV1 agonist NADA (10 nmol) or vehicle (VEH) was 
injected intrathecally (IT) with or without a co-injection of 
the TRPV1 antagonist AMG 9810 (1 nmol) and the hindpaws 
were stimulated with a cotton bud 15 (A) and 60 min (B) 
after the IT injection. NADA (10 nmol) or VEH was injected 
IT with or without a co-injection of the NKCC1 antagonist 
bumetanide (BUM, 1 nmol) and the hindpaws were stimu-
lated with a cotton bud 15 (C) and 60 min (D) after the IT 
injection. Response frequencies to the cotton bud stimula-
tion are shown. Stars (*) above columns indicate significant 
effects of NADA vs. VEH while number signs (#) above hori-
zontal bars indicate significant effects of antagonists (one-way 
anova, * or # p < 0.05, ** or ## p < 0.01; n = 6 per group).Molecular Pain 2007, 3:17 http://www.molecularpain.com/content/3/1/17
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lated by neural activity [25]. NADA causes nocifensive
behaviors and hyperalgesia when it is applied in the
periphery [23,24] but its behavioral effect when injected
into the spinal cord has not been explored. IT NADA did
not cause nocifensive behaviors and had only a minor
effect on punctate hyperalgesia (at 8 mN), however, it
caused a robust stroking allodynia that was TRPV1-
dependent. To our knowledge this is the first demonstra-
tion that an endogenous TRPV1 agonist causes allodynia
when applied directly to the spinal cord further support-
ing the hypothesis that CNS TRPV1 receptors are critical
for inflammatory allodynia [17].
NADA-mediated stroking allodynia was inhibited by the
NKCC1 inhibitor, BUM, suggesting a role for NKCC1 in
this effect. In NKCC1 knockout mice, hindpaw inflamma-
tion-mediated punctate hyperalgesia (von Frey) is pre-
served but stroking allodynia (cotton bud) is absent [8].
Our current observations with NADA and BUM are con-
sistent with these findings from NKCC1 knockout mice
insofar as stroking (or dynamic) allodynia appears to be
the modality most affected in the hindpaw. It is unclear
why punctate hyperalgesia and/or allodynia are not
affected, however, dynamic allodynia has been suggested
to be reflective of an interaction between Aβ- and C-fibers
in the CNS following a sensitizing stimulus in experimen-
tal pain or in clinical pain in humans [31,32]. Mecha-
nisms for increasing the activity of NKCC1 in primary
afferent terminals have not been identified. In other CNS
areas stimuli such as mGluR agonists and calcium-sensi-
tive kinases are known to increase NKCC1 phosphoryla-
tion and activity [33]. TRPV1 activation stimulates
extracellular regulated kinase 1&2 (ERK) [34] and cal-
cium/calmodulin-dependent kinase II α (CaMKIα) [35]
activity both of which are kinases known to regulate
NKCC1 activity [33,36]. Both ERK [18] and CaMKIIα [37]
are involved in referred hyperalgesia evoked by intraco-
lonic capsaicin hence, an intriguing hypothesis is that IT
NADA activates ERK and/or CaMKIIα leading to an
increase in NKCC1 activity causing touch evoked pain. On
the other hand, it is possible that spinal TRPV1 activation
mediates allodynia by regulating GABAergic neurotrans-
mission. In this regard, it has been shown that dorsal horn
TRPV1 stimulation leads to a large increase in GABAergic
network activity [38] which may be an alternative expla-
nation for the role of NKCC1 in allodynia mediated by
NADA. Clearly more work is needed to better understand
the potential interplay between NKCC1 and TRPV1 and
its role in allodynia; however, the anti-allodynic effects
TRPV1 antagonists and NKCC1 inhibitors on the spinal
level indicate that this might be a fruitful avenue for com-
bined therapeutics.
Conclusion
We have demonstrated that spinal NKCC1 blockade and
spinal TRPV1 antagonism attenuates referred allodynia in
response to a painful visceral stimulus. Moreover, we have
shown that the endogenous TRPV1 agonist NADA,
applied spinally, evokes stroking allodynia in the hind-
paw that is TRPV1-dependent and inhibited by the
NKCC1 blocker BUM. These findings further implicate
NKCC1 in inflammatory allodynia and suggest that spinal
TRPV1 receptors might be involved in regulating NKCC1
activity in nociceptive primary afferents.
Methods
Animals
Male C57BL6 mice between 20–25 g were used for all
experiments. Experiments were in accordance with the
Canadian Counsel on Animal Care (CCAC) and the Inter-
national Association for the Study of Pain (IASP) guide-
lines for the care and use of experimental animals. All
protocols were reviewed and approved by the McGill Uni-
versity Animal Care Committee.
Behavioral Testing and Statistical Analysis
Mice were habituated to a Plexiglass testing box (10 × 10
× 8 cm) for 1–2 hours prior to testing. The model of
referred allodynia has been described previously [19],
briefly, just prior to application of CAP, petroleum jelly
(Vaseline) was applied to the peri-anal area to avoid the
stimulation of somatic areas by contact with the capsaicin.
A total of 0.05 ml of 0.1% capsaicin solution was slowly
injected via a fine cannula with a rounded tip (external
diameter 0.61 mm), gently introduced 4 cm into the
colon via the anus. Capsaicin (0.1%, Tocris, Ellisville,
MO) was dissolved in 10% ethanol, 10% Tween 80 and
80% saline. Bumetanide (BUM; Sigma, St. Louis, MO),
AMG 9810 (Tocris) and n-arachidonoyl- dopamine
(NADA, Tocris) were dissolved in artificial cerebrospinal
fluid (aCSF) vehicle. The aCSF vehicle was comprised of
(in mM) 1.3 CaCl2 2H2O, 2.6 KCl, 0.9 MgCl, 21.0
NaHCO3, 2.5 Na2HPO47H2O, 125.0 NaCl, and 3.5 dex-
trose (pH 7.2–7.4). Intrathecal (IT) injections of BUM,
AMG 9801 and NADA were made in 5 μl aCSF on lightly
anesthetized mice by lumbar puncture at the L4–L5 level
with a 30-gauge needle on a 50 μl Hamilton needle [39].
Referred visceral hyperalgesia was tested on the abdomen
with calibrated von Frey filaments (1mN & 32 mN) at var-
ious time-points before or after intracolonic capsaicin
treatment. Percent response frequency was calculated
from the number of responses to 10 stimulations on the
abdomen. Each filament was applied for approximately
1–2 s, with an inter-stimulus interval of 2–5 s. The appear-
ance of any of the following behaviors on application of a
filament to the abdomen was considered a withdrawal
response: (i) sharp retraction of the abdomen, (ii) imme-
diate licking or scratching of site of application of fila-Molecular Pain 2007, 3:17 http://www.molecularpain.com/content/3/1/17
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ment, or (iii) jumping. For experiments with NADA, mice
were habituated as above and tested on the hindpaw with
von Frey filaments of 1, 4, 8 and 16 mN using the same
protocol as for abdominal testing. Mice were also tested
for stroking allodynia by gently brushing the plantar sur-
face of the hindpaw 10 times with a 5 sec inter-stimulus
interval with a cotton bud (Q-tip). The following reac-
tions were considered a withdrawal response to the cotton
bud: (i) sharp retraction of hindpaw, (ii) immediate lick-
ing or scratching of site of application of the cotton bud,
or (iii) jumping. Mice were used for only one experimen-
tal procedure and were humanely killed by anesthesia
overdose immediately after testing. All testing was per-
formed blind to condition and treatment. Data are shown
as mean ± SEM and all analyses involved one or two way
anova (indicated in figure captions) with bonferroni post-
tests, where p < 0.05 was considered significant.
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